A review of the role of levocetirizine as an effective therapy for allergic disease

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 5, 2008, Pages 859-867

  Walsh, Garry M ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Allergy; Anti inflammatory; Antihistamine; Levocetirizine

Indexed keywords

ANTIHISTAMINIC AGENT; CETIRIZINE; CHLORPHENIRAMINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DECONGESTIVE AGENT; DESLORATADINE; DIPHENHYDRAMINE; EBASTINE; FEXOFENADINE; HISTAMINE H1 RECEPTOR; HISTAMINE H1 RECEPTOR ANTAGONIST; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LEVOCETIRIZINE; LORATADINE; MIZOLASTINE; MOXIFLOXACIN; PLACEBO; PROMETHAZINE; SALBUTAMOL; ANTIINFLAMMATORY AGENT; PIPERAZINE DERIVATIVE;

ADD ON THERAPY; ALLERGIC ASTHMA; ALLERGIC DISEASE; ALLERGIC RHINITIS; AMNESIA; ANTIINFLAMMATORY ACTIVITY; ATTENTION DISTURBANCE; BINDING AFFINITY; CARDIOTOXICITY; CHRONIC URTICARIA; CLINICAL TRIAL; COGNITIVE DEFECT; COST EFFECTIVENESS ANALYSIS; DESENSITIZATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ENANTIOMER; HEALTH CARE COST; HUMAN; IDIOPATHIC DISEASE; LIVER METABOLISM; LONG TERM CARE; MEDLINE; OPTIMAL DRUG DOSE; PSYCHOMOTOR DISORDER; PSYCHOMOTOR RETARDATION; REPEATED DRUG DOSE; REVIEW; SEDATION; SHORT COURSE THERAPY; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; UNSPECIFIED SIDE EFFECT; ADULT; BIOAVAILABILITY; CHILD; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; METABOLISM; RHINITIS; URTICARIA;

ADULT; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL AVAILABILITY; CETIRIZINE; CHILD; CONTROLLED CLINICAL TRIALS AS TOPIC; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; PIPERAZINES; RECEPTORS, HISTAMINE H1; RHINITIS; URTICARIA;

EID: 41949083066     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.5.859     Document Type: Review

References (48)

1. Leurs R, Church MK, Taglialatela M. H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy 2002;32:489-98
2. Walsh GM, Annunziatto L, Frossard N, et al. New insights into the second generation antihistamines. Drugs 2001;61:207-36
3. Simons FE. Advances in H1-antihistamines. N Engl J Med 2004;351:2203-17
4. Hair PI, Scott LJ. Levocetirizine: a review of its use in the management of allergic rhinitis and skin allergies. Drugs 2006;66:973-96
5. Dubuske LM. Levocetirizine: the latest treatment option for allergic rhinitis and chronic idiopathic urticaria. Allergy Asthma Proc 2007;28:724-34
6. Thomson L, Blaylock MG, Sexton DW, et al. Cetirizine and levocetirizine inhibit eotaxin-induced eosinophil transendothelial migration through human dermal or lung microvascular endothelial cells. Clin Exp Allergy 2002;32:1187-92
7. Wu P, Mitchell S, Walsh GM. A new antihistamine levocetirizine inhibits eosinophil adhesion to vascular cell adhesion molecule-1 under flow conditions. Clin Exp Allergy 2005;35:1073-9
8. Menzies-Gow A, Ying S, Phipps S, Kay AB. Interactions between eotaxin, histamine and mast cells in early microvascular events associated with eosinophil recruitment to the site of allergic skin reactions in humans. Clin Exp Allergy 2004;34:1276
9. Giustizieri ML, Albanesi C, Fluhr J, et al. H1 histamine receptor mediates inflammatory responses in human keratinocytes. J Allergy Clin Immunol 2004;114:1176-82
10. Petecchia L, Serpero L, Silvestri M, et al. The histamine-induced enhanced expression of vascular cell adhesion molecule-1 by nasal polyp-derived fibroblasts is inhibited by levocetirizine. Am J Rhinol 2006;20:445-9
11. Hasala H, Janka-Junttila M, Moilanen E, Kankaanranta H. Levocetirizine and cytokine production and apoptosis of human eosinophils. Allergy Asthma Proc 2007;28:582-91
12. Ciprandi G, Cirillo I, Vizzaccaro A, Tosca MA. Levocetirizine improves nasal obstruction and modulates cytokine pattern in patients with seasonal allergic rhinitis: a pilot study. Clin Exp Allergy 2004;34:958-64
13. Frossard N, Strolin-Benedetti M, Purohit A, Pauli G. Inhibition of allergen-induced wheal and flare reactions by levocetirizine and desloratadine. Br J Clin Pharmacol 2008;65(2):172-9
14. Walsh GM. Second-generation antihistamines in asthma therapy - is there a protective effect? Am J Respir Med 2002;1:27-34
15. Lee DK, Gray RD, Wilson AM, et al. Single and short-term dosing effects of levocetirizine on adenosine monophosphate bronchoprovocation in atopic asthma. Br J Clin Pharmacol 2004;58:34-9
16. Lipworth BJ, White PS. Allergic inflammation in the unified airway: start with the nose. Thorax 2000;55:878-81
17. Pasquali M, Baiardini I, Rogkakou A, et al. Levocetirizine in persistent allergic rhinitis and asthma: effects on symptoms, quality of life and inflammatory parameters. Clin Exp Allergy 2006;36:1161-7
18. Clough GF, Boutsiouki P, Church MK. Comparison of the effects of levocetirizine and loratadine on histamine-induced wheal, flare, and itch in human skin. Allergy 2001;56:985-8
19. Grant JA, Riethuisen JM, Moulaert B, DeVos C. A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. Ann Allergy Asthma Immunol 2002;88:190-7
20. Devalia JL, De Vos C, Hanotte F, Baltes E. A randomized, double-blind, crossover comparison among cetirizine, levocetirizine, and ucb 28557 on histamine-induced cutaneous responses in healthy adult volunteers. Allergy 2001;56:50-7
21. Popov TA, Dumitrascu D, Bachvarova A, et al. A comparison of levocetirizine and desloratadine in the histamine-induced wheal and flare response in human skin in vivo. Inflamm Res 2006;55:241-4
22. Klos K, Kruszewski J, Kruszewski R, Sulek K. Effect of 5-days of cetirizine, desloratadine, fexofenadine 120 and 180 mg, levacetirizine and loratadine on histamine-induced skin reactivity and skin blood flow - a randomized, double-blind placebo-controlled trial. Pol Merk Lek 2006;21:449-53
23. Baltes E, Coupez R, Giezek H, et al. Absorption and disposition of levocetirizine, the eutomer of cetirizine, administered alone or as cetirizine to healthy volunteers. Fundam Clin Pharmacol 2001;15:269-77
24. Molimard M, Diquet B, Benedetti MS. Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fundam Clin Pharmacol 2004;8:399-411
25. Simons FE, Simons KJ. Levocetirizine: pharmacokinetics and pharmacodynamics in children age 6 to 11 years. J Allergy Clin Immunol 2005;116:355-61
26. Walsh GM. Levocetirizine: an update. Curr Med Chem 2006;13:2711-5
27. Ciprandi G, Cirillo IG, Vizzaccaro A, Tosca MA. Levocetirizine improves nasal symptoms and airflow in patients with persistent allergic rhinitis: a pilot study. Allerg Immunol (Paris) 2005;37:25-9
28. Bachert C, Bousquet J, Canonica GW, et al.; XPERT Study Group. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol 2004;114:838-44
29. Bousquet J, Demarteau N, Mullol J, et al.; XPERT Study Group. Costs associated with persistent allergic rhinitis are reduced by levocetirizine. Allergy 2005;60:788-94
30. Passalacqua G, Guerra L, Compalati E, et al. Comparison of the effects in the nose and skin of a single dose of desloratadine and levocetirizine over 24 hours. Int Arch Allergy Immunol 2004;135:143-7
31. Patou J, De Smedt H, van Cauwenberge P, Bachert C. Pathophysiology of nasal obstruction and meta-analysis of early and late effects of levocetirizine. Clin Exp Allergy 2006;36:972-81
32. White MV, Kaliner MA. Mediators of allergic rhinitis. J Allergy Clin Immunol 1992;90:699-704
33. Monroe E. Review of H1 antihistamines in the treatment of chronic idiopathic urticaria. Cutis 2005;76:118-26
34. Kapp A, Wedi B. Chronic urticaria: clinical aspects and focus on a new antihistamine, levocetirizine. J Drugs Dermatol 2004;3:632-9
35. Nettis E, Colanardi MC, Barra L, et al. Levocetirizine in the treatment of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Br J Dermatol 2006;154:533-8
36. Kapp A, Pichler WJ. Levocetirizine is an effective treatment in patients suffering from chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, parallel, multicenter study. Int J Dermatol 2006;45:469-74
37. Kapp A, Demarteau N. Cost effectiveness of levocetirizine in chronic idiopathic urticaria: a pooled analysis of two randomised controlled trials. Clin Drug Investig 2006;26:1-11
38. Caproni M, Volpi W, Giomi B, et al. Cellular adhesion molecules in chronic urticaria: modulation of serum levels occurs during levocetirizine treatment. Br J Dermatol 2006;155:1270-4
39. de Blic J, Wahn U, Billard E, et al. Levocetirizine in children: evidenced efficacy and safety in a 6-week randomized seasonal allergic rhinitis trial. Pediatr Allergy Immunol 2005;16:267-75
40. Potter PC. Efficacy and safety of levocetirizine on symptoms and health-related quality of life of children with perennial allergic rhinitis: a double-blind, placebo-controlled randomized clinical trial. Ann Allergy Asthma Immunol 2005;95:175-85
41. Simons FE; Early Prevention of Asthma in Atopic Children Study Group. H1-antihistamine treatment in young atopic children: effect on urticaria. Ann Allergy Asthma Immunol 2007;99:261-6
42. Verster JC, De Weert AM, Bijtjes SI, et al. Driving ability after acute and sub-chronic administration of levocetirizine and diphenhydramine: a randomized, double-blind, placebo-controlled trial. Psychopharmacology (Berl) 2003;169:84-90
43. Verster JC, Volkerts ER, van Oosterwijck AW, et al. Acute and subchronic effects of levocetirizine and diphenhydramine on memory functioning, psychomotor performance, and mood. J Allergy Clin Immunol 2003;111:623-7
44. Gandon JM, Allain H. Lack of effect of single and repeated doses of levocetirizine, a new antihistamine drug, on cognitive and psychomotor functions in healthy volunteers. Br J Clin Pharmacol 2002;54:51-8
45. Yap YG, Camm AJ. Potential cardiac toxicity of H1-antihistamines. Clin Allergy Immunol 2002;17:389-419
46. Hulhoven R, Rosillon D, Letiexhe M, et al. Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study. Eur J Clin Pharmacol 2007;63:1011-7
47. Simons FE; Early Prevention of Asthma in Atopic Children (EPAAC) Study Group. Safety of levocetirizine treatment in young atopic children: an 18-month study. Pediatr Allergy Immunol 2007;6:535-42
48. Patil PA, Kothekar MA. Development of safer molecules through chirality. Indian J Med Sci 2006;60:427-37